



**Australian Government**  
**Department of Health**

# COMMUNICABLE DISEASES INTELLIGENCE

2020 Volume 44  
<https://doi.org/10.33321/cdi.2020.44.18>

## **Australian Group on Antimicrobial Resistance (AGAR) Australian *Staphylococcus aureus* Sepsis Outcome Programme (ASSOP) Annual Report 2018**

Geoffrey W Coombs, Denise A Daley, Shakeel Mowlaboccus, Yung  
Thin Lee and Stanley Pang, on behalf of the Australian Group on  
Antimicrobial Resistance

# Communicable Diseases Intelligence

ISSN: 2209-6051 Online

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2020 Commonwealth of Australia as represented by the Department of Health

This publication is licensed under a Creative Commons Attribution-Non-Commercial NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

## Restrictions

The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

- the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au));
- any logos (including the Department of Health's logo) and trademarks;
- any photographs and images;
- any signatures; and
- any material belonging to third parties.

## Disclaimer

Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health or the Communicable Diseases Network Australia. Data may be subject to revision.

## Enquiries

Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health, GPO Box 9848, Canberra ACT 2601, or via e-mail to: [copyright@health.gov.au](mailto:copyright@health.gov.au)

## Communicable Diseases Network Australia

Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.  
<http://www.health.gov.au/cdna>



Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.

## Editor

Cindy Toms

## Deputy Editor

Simon Petrie

## Design and Production

Kasra Yousefi

## Editorial Advisory Board

David Durrheim,  
Mark Ferson, John Kaldor,  
Martyn Kirk and Linda Selvey

## Website

<http://www.health.gov.au/cdi>

## Contacts

Communicable Diseases Intelligence is produced by:  
Health Protection Policy Branch  
Office of Health Protection  
Australian Government  
Department of Health  
GPO Box 9848, (MDP 6)  
CANBERRA ACT 2601

## Email:

[cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)

## Submit an Article

You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at:  
<http://health.gov.au/cdi>.

Further enquiries should be directed to:  
[cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au).

# Australian Group on Antimicrobial Resistance (AGAR) Australian *Staphylococcus aureus* Sepsis Outcome Programme (ASSOP) Annual Report 2018

Geoffrey W Coombs, Denise A Daley, Shakeel Mowlaboccus, Yung Thin Lee and Stanley Pang, on behalf of the Australian Group on Antimicrobial Resistance

## Abstract

From 1 January to 31 December 2018, thirty-six institutions around Australia participated in the Australian *Staphylococcus aureus* Sepsis Outcome Programme (ASSOP). The aim of ASSOP 2018 was to determine the proportion of *Staphylococcus aureus* bacteraemia (SAB) isolates in Australia that are antimicrobial resistant, with particular emphasis on susceptibility to methicillin, and to characterise the molecular epidemiology of the methicillin-resistant isolates. A total of 2,673 *S. aureus* bacteraemia episodes were reported, of which 78.9% were community-onset. A total of 17.4% of *S. aureus* isolates were methicillin resistant. The 30-day all-cause mortality associated with methicillin-resistant SAB was 17.1% which was not significantly higher than the 13.6% mortality associated with methicillin-susceptible SAB ( $p = 0.1$ ). With the exception of the  $\beta$ -lactams and erythromycin, antimicrobial resistance in methicillin-susceptible *S. aureus* was rare. However in addition to the  $\beta$ -lactams approximately 42% of methicillin-resistant *S. aureus* (MRSA) were resistant to erythromycin, 36% to ciprofloxacin and approximately 13% resistant to co-trimoxazole, tetracycline and gentamicin. When applying the EUCAST breakpoints teicoplanin resistance was detected in two *S. aureus* isolates. Resistance was not detected for vancomycin and linezolid. Resistance to non-beta-lactam antimicrobials was largely attributable to two healthcare-associated MRSA clones: ST22-IV [2B] (EMRSA-15) and ST239-III [3A] (Aus-2/3 EMRSA). The ST22-IV [2B] (EMRSA-15) clone is the predominant healthcare-associated clone in Australia. Seventy eight percent of methicillin-resistant SAB episodes in 2018 were due to community-associated clones. Although polyclonal, approximately 76.3% of community-associated clones were characterised as ST93-IV [2B] (Queensland CA-MRSA), ST5-IV [2B], ST45-V<sub>T</sub> [5C2&5], ST1-IV [2B], ST30-IV [2B], ST78-IV [2B] and ST97-IV [2B]. Community-associated MRSA, in particular the ST45-V<sub>T</sub> [5C2&5] clone, has acquired multiple antimicrobial resistance determinants including ciprofloxacin, erythromycin, clindamycin, gentamicin and tetracycline. The ST45-V<sub>T</sub> [5C2&5] clone accounted for 11.7% of CA-MRSA. As CA-MRSA is well established in the Australian community, it is important that antimicrobial resistance patterns in community- and healthcare-associated SAB are monitored, as this information will guide therapeutic practices in treating *S. aureus* sepsis.

**Keywords:** Australian Group on Antimicrobial Resistance (AGAR); antimicrobial resistance surveillance; *Staphylococcus aureus*; methicillin-susceptible *Staphylococcus aureus* (MSSA); methicillin-resistant *Staphylococcus aureus* (MRSA); bacteraemia

## Background

Globally, *Staphylococcus aureus* is one of the most frequent causes of hospital-acquired and community-acquired bloodstream infections.<sup>1</sup> Although there are a wide variety of manifestations of serious invasive infection caused by *S. aureus*, in the great majority of these cases the organism can be detected in blood cultures. Therefore, *S. aureus* bacteraemia (SAB) is considered a very useful marker for serious invasive infection.<sup>2</sup>

Although prolonged antimicrobial therapy and prompt source control are used to treat SAB,<sup>3</sup> mortality ranges from as low as 2.5% to as high as 40%.<sup>4–6</sup> Mortality rates, however, are known to vary significantly with patient age, clinical manifestation, comorbidities and methicillin resistance.<sup>7,8</sup> A prospective study of SAB conducted in 27 laboratories in Australia and New Zealand found a 30-day all-cause mortality of 20.6%.<sup>9</sup> On univariate analysis, increased mortality was significantly associated with older age, European ethnicity, methicillin resistance, infections not originating from a medical device, sepsis syndrome, pneumonia/empyema, and treatment with a glycopeptide or other non- $\beta$ -lactam antibiotic.

The Australian Group on Antimicrobial Resistance (AGAR), a network of laboratories located across Australia, commenced surveillance of antimicrobial resistance in *S. aureus* in 1986.<sup>10</sup> In 2013 AGAR commenced the Australian *Staphylococcus aureus* Sepsis Outcome Programme (ASSOP).<sup>11</sup> The primary objective of ASSOP 2018 was to determine the proportion of SAB isolates demonstrating antimicrobial resistance with particular emphasis on:

1. assessing susceptibility to methicillin
2. molecular epidemiology of methicillin-resistant *S. aureus* (MRSA).

## Methodology

### Participants

Thirty-six laboratories from all eight Australian states and mainland territories.

### Collection period

From 1 January to 31 December 2018, the 36 laboratories collected all *S. aureus* isolated from blood cultures. *S. aureus* with the same antimicrobial susceptibility profiles isolated from a patient's blood culture within 14 days of the first positive culture were excluded. A new *S. aureus* sepsis episode in the same patient was recorded if it was identified by a culture of blood collected more than 14 days after the last positive culture. Data were collected on age, sex, date of admission and discharge (if admitted), and mortality at 30 days from date of first positive blood culture. To avoid interpretive bias, no attempt was made to assign attributable mortality. Each episode of bacteraemia was designated hospital-onset if the first positive blood culture(s) in an episode were collected > 48 hours after admission.

### Laboratory testing

Participating laboratories performed antimicrobial susceptibility testing using the Vitek2<sup>®</sup> (bioMérieux, France) or the Phoenix<sup>™</sup> (Becton Dickinson, USA) automated microbiology systems according to the manufacturer's instructions. Identification of *S. aureus* was by morphology and by a positive result from at least one of the following tests: Vitek MS<sup>®</sup> (bioMérieux), matrix-assisted laser desorption ionization (MALDI) biotyper (Bruker Daltonics, USA), slide coagulase, tube coagulase, appropriate growth on chromogenic agar and demonstration of deoxyribonuclease production. Additional tests such as fermentation of mannitol, growth on mannitol-salt agar or polymerase chain reaction (PCR) for the presence of the *nuc* gene may have been performed for confirmation.

Minimum inhibitory concentration (MIC) data and isolates were referred to the Antimicrobial

Resistance and Infectious Diseases (AMRID) Research Laboratory at Murdoch University. Clinical and Laboratory Standards Institute (CLSI)<sup>12</sup> and European Committee on Antimicrobial Susceptibility Testing (EUCAST)<sup>13</sup> breakpoints were utilised for interpretation. Isolates with a resistant or an intermediate category were classified as non-susceptible. Linezolid and daptomycin non-susceptible isolates were retested by Etest<sup>®</sup> (bioMérieux) using the Mueller-Hinton agar recommended by the manufacturer. The control strain used was *S. aureus* ATCC 29213. High-level mupirocin resistance was determined by the Phoenix<sup>™</sup> or by using a mupirocin 200 µg disk according to CLSI guidelines on all isolates with a mupirocin MIC > 8 mg/L by Vitek2<sup>®</sup>. Multi-resistance was defined as resistance to three or more of the following non-β-lactam antimicrobials: vancomycin, teicoplanin, erythromycin/clindamycin, tetracycline, ciprofloxacin, gentamicin, cotrimoxazole, fusidic acid, rifampicin, high-level mupirocin, and linezolid.

Molecular testing was performed by whole genome sequencing (WGS) using the NextSeq platform (Illumina, San Diego, USA). Sequencing results were analysed using the Nullarbor pipeline.<sup>14</sup> The spaTyper tool<sup>15</sup> was applied to sequence data to determine *spa* types. SCCmec was determined using KmerFinder V 3.1,<sup>16</sup> and using the SCCmec database curated from the CGE database.<sup>17,18</sup>

Chi-squared tests for comparison of two proportions and calculation of 95% confidence intervals (95% CI) were performed using MedCalc for Windows, version 12.7 (MedCalc Software, Ostend Belgium).

Approval to conduct the prospective data collection was given by the research ethics committee associated with each participating laboratory.

## Results

From 1 January to 31 December 2018, a total of 2,673 unique episodes of *S. aureus* bacteraemia were identified. A significant imbalance ( $p <$

0.0001) was seen in patient sex, with 64.1% (1,713) being male (95% CI 62.3–65.9). The average age of patients was 57 years ranging from 0–100 years with a median age of 61 years. Overall 78.9% (2,108/2,673) of episodes were community onset (95% CI 77.3–80.4). All-cause mortality at 30 days was 14.2% (95% CI 12.7–15.8). Methicillin-resistant SAB mortality was 17.1% (95% CI 13.3–21.4) which was not significantly higher than for methicillin-susceptible SAB mortality (13.6%, 95% CI 12.0–15.3) ( $p = 0.1$ ).

## Methicillin-susceptible *Staphylococcus aureus* (MSSA) antimicrobial susceptibility

Overall, 82.6% (2,207) of the 2,673 isolates were methicillin susceptible of which 74.7% (1,649) were penicillin resistant (MIC > 0.12 mg/L). However as β-lactamase was detected in 91 phenotypically penicillin-susceptible isolates, 79.0% of MSSA were considered penicillin resistant. Apart from erythromycin non-susceptibility (18.0% and 10.7% using CLSI and EUCAST breakpoints respectively), resistance to the non-β-lactam antimicrobials amongst MSSA was rare, ranging from 0% to 3.2% (Table 1). There were six isolates reported by Vitek2<sup>®</sup> as non-susceptible to daptomycin (MIC > 1.0 mg/L). By Etest<sup>®</sup>, five of the isolates were considered susceptible (MICs 0.25–1.0 mg/L). The remaining isolate had an MIC of 2.0 mg/L and was confirmed as non-susceptible, however using WGS no known daptomycin mutations were identified. By Vitek2<sup>®</sup>, one isolate was linezolid resistant (MIC > 4 mg/L). However by Etest<sup>®</sup>, the isolate had an MIC ≤ 4 mg/L (2.0 mg/L) and was therefore considered linezolid susceptible. All MSSA were vancomycin and teicoplanin susceptible. Twenty-eight (1.3%) of 2,195 isolates had high-level mupirocin resistance, of which 20 isolates were referred from Queensland. Sixteen of the twenty-eight mupirocin-resistant MSSA were also resistant to fusidic acid. Inducible resistance to clindamycin was determined by the Vitek2<sup>®</sup> susceptibility system. Of the 1,880 isolates tested, 19.1% (360) were erythromycin non-susceptible / clindamycin susceptible (CLSI breakpoints) of which 51.7% (186) were classi-

**Table 1: The number and proportion of methicillin-susceptible *Staphylococcus aureus* (MSSA) isolates non-susceptible to penicillin and the non- $\beta$ -lactam antimicrobials, Australia, 2018**

Antimicrobial	Number tested	Breakpoint (mg/L)	Non-susceptible	
			n	%
Penicillin <sup>a</sup>	2,202	> 0.12 <sup>b</sup>	1,740	79.0
Vancomycin	2,206	> 2 <sup>b</sup>	0	0.0
Teicoplanin	2,206	> 8 <sup>c</sup>	0	0.0
		> 2 <sup>d</sup>	0	0.0
Rifampicin	2,200	> 1 <sup>c</sup>	7	0.3
		> 0.5 <sup>d</sup>	7	0.3
Fusidic Acid	2,202	> 1 <sup>d</sup>	71	3.2
Gentamicin	2,202	> 4 <sup>c</sup>	15	0.7
		> 1 <sup>d</sup>	28	1.3
Erythromycin	2,149	> 0.5 <sup>c</sup>	387	18.0
		> 2 <sup>d</sup>	231	10.7
Clindamycin	2,201	> 0.5 <sup>b</sup>	30	1.4
Tetracycline/doxycycline	2,202	> 4 <sup>c</sup>	59	2.7
		> 2 <sup>d</sup>	66	3.0
Co-trimoxazole	2,200	> 2/38 <sup>c</sup>	66	3.0
		> 4/76 <sup>d</sup>	49	2.2
Ciprofloxacin	2,202	> 1 <sup>b</sup>	60	2.7
Nitrofurantoin	2,041	> 32 <sup>c</sup>	12	0.6
Daptomycin	2,206	> 1 <sup>b</sup>	1	0.05
Linezolid	2,206	> 4 <sup>b</sup>	0	0
High-level mupirocin	2,144	> 256 <sup>c</sup>	28	1.3

a  $\beta$ -lactamase adjusted

b CLSI and EUCAST non-susceptible breakpoint

c CLSI non-susceptible breakpoint

d EUCAST non-susceptible breakpoint

fied as having inducible clindamycin resistance. Multi-resistance was uncommon in MSSA (1.8%, 38/2,144).

There were no significant differences in antimicrobial interpretation when CLSI or EUCAST non susceptibility breakpoints were utilised ( $p > 0.05$ ).

### MRSA antimicrobial susceptibility

The proportion of *S. aureus* that were MRSA was 17.4% (95% CI 16.0–18.9). Of the 466 MRSA identified, 404 were ceftioxin screen positive by Vitek2<sup>®</sup> and 62 had a ceftioxin MIC > 4 mg/L by Phoenix<sup>™</sup>. Six of the 466 MRSA isolates were phenotypically penicillin susceptible (MIC ≤ 0.125 mg/L), however β-lactamase was detected in all six. Amongst the MRSA isolates, non-susceptibility to non-β-lactam antimicrobials was common except for nitrofurantoin, rifampicin and fusidic acid where resistance ranged from 1.6% to 4.5% (Table 2). All MRSA were vancomycin susceptible. There were nine isolates reported by Vitek2<sup>®</sup> as non-susceptible to daptomycin (MIC > 1.0 mg/L). One isolate was not available for confirmation. By Etest<sup>®</sup>, three of the isolates were considered susceptible (MIC 1.0 mg/L). The remaining five isolates had Etest<sup>®</sup> MICs of 1.5 mg/L (two isolates) and 2.0 mg/L (three isolates) and therefore were considered non-susceptible. Using WGS, daptomycin non-susceptibility in two isolates was due to single point mutations in the *mprF* gene: *mprF*-L826F and *mprF*-S295L. No known daptomycin mutations were found in the other three isolates.

By Vitek2<sup>®</sup>, one isolate was linezolid resistant (MIC > 4 mg/L). However by Etest<sup>®</sup>, the isolate had an MIC ≤ 4 mg/L (1.0 mg/L) and was therefore considered linezolid susceptible. When using the EUCAST resistant breakpoint of > 2 mg/L, two isolates were teicoplanin resistant (MIC = 4 mg/L). However, using the CLSI resistant breakpoint of > 8 mg/L, the isolates were classified as susceptible. Nine (1.9%) of 464 MRSA isolates tested had high-level mupirocin resistance, of which four were from Queensland.

Inducible resistance to clindamycin was determined by the Vitek2<sup>®</sup> susceptibility system. Of the 380 isolates tested by Vitek2<sup>®</sup>, 35.3% (134) were erythromycin non-susceptible / clindamycin susceptible (CLSI and EUCAST breakpoints), of which 61.9% (83) were classified as having inducible clindamycin resistance. Multi-resistance was seen in 40.3% (181/449) of MRSA.

There were no significant differences in interpretation for any drug when CLSI or EUCAST non-susceptibility breakpoints were utilised.

### MRSA molecular epidemiology

WGS was performed on 96.4% (449/466) of the MRSA. Based on molecular typing, 22.0% (99/449) and 78.0% (350/449) of isolates were identified as healthcare-associated MRSA (HA-MRSA) and community-associated MRSA (CA-MRSA) clones respectively (Table 3).

#### Healthcare-associated methicillin-resistant *Staphylococcus aureus*

For the 99 HA-MRSA isolates, 36.4% (36/99) were epidemiologically classified as hospital-onset and 63.6% (63/99) were classified as community-onset. Three HA-MRSA clones were identified: 81 isolates of ST22-IV [2B] (EMRSA-15) (18% of MRSA typed and 3.0% of *S. aureus*); 17 isolates of ST239-III [3A] (Aus-2/3 EMRSA) (3.8% and 0.6%), and one isolate of ST8-II (Irish EMRSA-1) (0.2% and 0.04%).

ST22-IV [2B] (EMRSA-15) was the dominant HA-MRSA clone in Australia accounting for 81.8% of HA-MRSA ranging from 0% in the Northern Territory to 100% in Tasmania (Table 4). The ST22-IV [2B] (EMRSA-15) clone is Panton-Valentine leucocidin (PVL) negative and using CLSI breakpoints 96.3% and 59.7% were ciprofloxacin and erythromycin non-susceptible respectively. Overall 37.0% of ST22-IV were hospital-onset.

ST239-III [3A] (Aus-2/3 EMRSA) accounted for 17.2% of HA-MRSA ranging from 0% in Western Australia, Tasmania and the Australian Capital

**Table 2: The number and proportion of methicillin-resistant *Staphylococcus aureus* (MRSA) isolates non-susceptible to penicillin and the non- $\beta$ -lactam antimicrobials, Australia, 2018**

Antimicrobial	Number tested	Breakpoint (mg/L)	Non-susceptible (%)	
			n	%
Penicillin	466	> 0.12 <sup>a</sup>	466	100
Vancomycin	466	> 2 <sup>a</sup>	0	0
Teicoplanin	466	> 8 <sup>b</sup>	0	0
		> 2 <sup>c</sup>	2	0.4
Rifampicin	466	> 1 <sup>b</sup>	8	1.7
		> 0.5 <sup>c</sup>	8	1.7
Fusidic Acid	464	> 1 <sup>c</sup>	21	4.5
Gentamicin	466	> 4 <sup>b</sup>	66	14.2
		> 1 <sup>c</sup>	72	15.5
Erythromycin	450	> 0.5 <sup>b</sup>	190	42.2
		> 2 <sup>c</sup>	174	38.7
Clindamycin	465	> 0.5 <sup>a</sup>	60	12.9
Tetracycline/ doxycycline	466	> 4 <sup>b</sup>	65	13.9
		> 2 <sup>c</sup>	74	15.9
Co-trimoxazole	464	> 2/38 <sup>b</sup>	49	10.6
		> 4/76 <sup>c</sup>	49	10.6
Ciprofloxacin	466	> 1 <sup>a</sup>	166	35.6
Nitrofurantoin	445	> 32 <sup>b</sup>	7	1.6
Daptomycin	466	> 1 <sup>a</sup>	5	1.1
Linezolid	466	> 4 <sup>a</sup>	0	0
High-level mupirocin	464	> 256 <sup>b</sup>	9	1.9

a CLSI and EUCAST non-susceptible breakpoint

b CLSI non-susceptible breakpoint

c EUCAST non-susceptible breakpoint

**Table 3: Proportion of healthcare-associated and community-associated methicillin-resistant *Staphylococcus aureus*, Australia, 2018 by clone, hospital and community onset, and Panton-Valentine leucocidin carriage**

Strain	Total		Onset				PVL positive	
	n	% <sup>a</sup>	Hospital		Community		n	% <sup>b</sup>
			n	% <sup>b</sup>	n	% <sup>b</sup>		
<b>Healthcare-associated MRSA</b>								
ST22-IV [2B] (EMRSA-15)	81	18.0%	30	37.0%	51	63.0%	–	–
ST239-III [3A] (Aus-2/3)	17	3.8%	6	35.3%	11	64.7%	–	–
ST8-II (Irish EMRSA-1)	1	0.2%	–	–	1	100.0%	–	–
<b>Total HA-MRSA</b>	<b>99</b>	<b>22.0%</b>	<b>36</b>	<b>36.4%</b>	<b>63</b>	<b>63.6%</b>	<b>0</b>	<b>0</b>
<b>Community-associated MRSA</b>								
ST93-IV [2B] (Queensland)	99	22.0%	11	11.1%	88	88.9%	95	96.0%
ST5-IV	44	9.8%	13	29.5%	31	70.5%	14	31.8%
ST45-V <sub>T</sub>	41	9.1%	12	29.3%	29	70.7%	–	–
ST1-IV	35	7.8%	6	17.1%	29	82.9%	1	2.9%
ST30-IV	21	4.7%	2	9.5%	19	90.5%	17	81.0%
ST97-IV	14	3.1%	2	14.3%	12	85.7%	–	–
ST78-IV	13	2.9%	3	23.1%	10	76.9%	–	–
ST5-V	8	1.8%	1	12.5%	7	87.5%	–	–
ST8-IV	8	1.8%	–	–	8	100.0%	5	62.5%
ST22-IV (PVL positive)	7	1.6%	1	14.3%	6	85.7%	7	100.0%
ST872-IV	7	1.6%	1	14.3%	6	85.7%	–	–
ST72-IV	5	1.1%	2	40.0%	3	60.0%	–	–
ST953-IV	5	1.1%	3	60.0%	2	40.0%	–	–
ST45-IV	3	0.7%	1	33.3%	2	66.7%	–	–
ST6-IV	3	0.7%	2	66.7%	1	33.3%	–	–
ST121-V	2	0.4%	1	50.0%	1	50.0%	–	–
ST188-IV	2	0.4%	1	50.0%	1	50.0%	–	–
ST2250-IV	2	0.4%	1	50.0%	1	50.0%	–	–
ST3628-II	2	0.4%	1	50.0%	1	50.0%	–	–
ST59-IV	2	0.4%	1	50.0%	1	50.0%	–	–
ST59-V	2	0.4%	–	–	2	100.0%	2	100.0%
ST835-I	2	0.4%	1	50.0%	1	50.0%	–	–
ST1043-V	1	0.2%	–	–	1	100.0%	–	–
ST1224-V	1	0.2%	–	–	1	100.0%	–	–
ST1232-V	1	0.2%	–	–	1	100.0%	1	100.0%
ST1482-IV	1	0.2%	–	–	1	100.0%	1	100.0%

Strain	Total		Onset				PVL positive	
	n	% <sup>a</sup>	Hospital		Community		n	% <sup>b</sup>
			n	% <sup>b</sup>	n	% <sup>b</sup>		
ST149-IV	1	0.2%	–	–	1	100.0%	–	–
ST15-IV	1	0.2%	–	–	1	100.0%	–	–
ST15-V	1	0.2%	1	100.0%	–	–	–	–
ST1649-IV	1	0.2%	–	–	1	100.0%	–	–
ST25-II	1	0.2%	–	–	1	100.0%	–	–
ST2611-II	1	0.2%	–	–	1	100.0%	–	–
ST2625-IV	1	0.2%	–	–	1	100.0%	–	–
ST30-V	1	0.2%	–	–	1	100.0%	1	100.0%
ST3628-V	1	0.2%	–	–	1	100.0%	–	–
ST398-V	1	0.2%	–	–	1	100.0%	–	–
ST5008-IV	1	0.2%	–	–	1	100.0%	–	–
ST508-IV	1	0.2%	1	100.0%	–	–	1	100.0%
ST6-V	1	0.2%	–	–	1	100.0%	–	–
ST73-IV	1	0.2%	–	–	1	100.0%	–	–
ST834-IV	1	0.2%	–	–	1	100.0%	–	–
ST835-IV	1	0.2%	–	–	1	100.0%	–	–
ST88-IV	1	0.2%	–	–	1	100.0%	–	–
ST923-IV	1	0.2%	–	–	1	100.0%	–	–
ST97-V	1	0.2%	–	–	1	100.0%	–	–
<b>Total CA-MRSA</b>	<b>350</b>	<b>78%</b>	<b>68</b>	<b>19.4%</b>	<b>282</b>	<b>80.6%</b>	<b>145</b>	<b>41.4%</b>
<b>Grand total</b>	<b>449</b>	<b>100%</b>	<b>104</b>	<b>23.2%</b>	<b>345</b>	<b>76.8%</b>	<b>145</b>	<b>32.3%</b>

a Percentage of all MRSA typed

b Percentage of the strain

**Table 4: The number and proportion of healthcare-associated methicillin-resistant *Staphylococcus aureus* (MRSA) multilocus sequence types, Australia, 2018, by region**

Type	ACT		NSW		NT		Qld		SA		Tas		Vic		WA		Aus	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
ST22-IV	3	75.0%	35	79.5%	-	-	5	50%	9	90.0%	6	100.0%	15	93.8%	8	100.0%	81	81.8%
ST239-III	-	-	9	20.5%	1	100.0%	5	50%	1	10.0%	-	-	1	6.3%	-	-	17	17.2%
ST8-II	1	25.0%	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1	1.0%
<b>Total</b>	<b>4</b>	<b>100.0%</b>	<b>44</b>	<b>100.0%</b>	<b>1</b>	<b>100.0%</b>	<b>10</b>	<b>100.0%</b>	<b>10</b>	<b>100.0%</b>	<b>6</b>	<b>100.0%</b>	<b>16</b>	<b>100.0%</b>	<b>8</b>	<b>100.0%</b>	<b>99</b>	<b>100.0%</b>

ACT = Australian Capital Territory; NSW = New South Wales; NT = Northern Territory; Qld = Queensland; SA = South Australia; Tas = Tasmania; Vic = Victoria; WA = Western Australia; Aus = Australia

Territory to 50.0% in the Northern Territory (Table 4). The PVL-negative ST239-III [3A] (Aus-2/3 EMRSA) isolates were typically resistant to erythromycin (100%), co-trimoxazole (94.1%), ciprofloxacin (100%), gentamicin (100%), tetracycline (81.3%) and clindamycin (75.0%). Overall 35.3% of ST239-III were hospital-onset.

### Community-associated methicillin-resistant *Staphylococcus aureus*

For the 350 CA-MRSA isolates, 19.4% (68) of episodes were epidemiologically classified as hospital-onset and 80.6% (282) classified as community-onset. Based on the multilocus sequence type and the SCC*mec* type, 45 CA-MRSA clones were identified (Table 3). Overall, 76.3% of CA-MRSA were classified into seven clones each having more than ten isolates: 99 isolates of ST93-IV [2B] (Queensland CA-MRSA) (22% of MRSA typed and 3.7% of *S. aureus*); 44 isolates of ST5-IV (9.8% and 1.6%); 41 isolates of ST45-V<sub>T</sub> (9.1% and 1.5%); 35 isolates of ST1-IV (7.8% and 1.3%); 21 isolates of ST30-IV (4.7% and 0.8%); 14 isolates of ST97-IV (3.1% and 0.5%) and 13 isolates of ST78-IV (2.9% and 0.5%).

ST93-IV [2B] (Queensland CA-MRSA) accounted for 28.3% of CA-MRSA, ranging from 0% in Tasmania to 67.9% in the Northern Territory (Table 5). Typically PVL positive, 76.8% (76/99) of ST93-IV [2B] (Queensland CA-MRSA) were resistant to the  $\beta$ -lactams only, other isolates were additionally resistant to erythromycin (5.1%, 5/99) or erythromycin and clindamycin (2.0%, 2/99). There were two isolates resistant to erythromycin and ciprofloxacin. Overall 88.9% of ST93-IV were community-onset.

ST5-IV accounted for 12.6% of CA-MRSA and was isolated in all regions of Australia except the Australian Capital Territory and Tasmania, ranging from 7.1% in South Australia to 21.5% in Queensland (Table 5). The ST5-IV isolates, of which 31.8% were PVL positive, were typically resistant to the  $\beta$ -lactams only, 34% (15/44). Isolates were additionally resistant to co-trimoxazole 20.5%, (9/44); erythromycin 13.6% (6/44), fusidic acid 9.1% (4/44) erythromycin and

co-trimoxazole (6.8%, 3/44); erythromycin and high-level mupirocin (4.5%, 2/44); and single isolates resistant to ciprofloxacin, erythromycin and high-level mupirocin; gentamicin and high-level mupirocin; erythromycin and tetracycline; and ciprofloxacin and erythromycin. Overall 70.7% of ST5-IV were community-onset.

ST45-V<sub>T</sub> accounted for 11.7% of CA-MRSA and was isolated primarily in New South Wales (Table 5). All isolates were PVL negative and were resistant to the  $\beta$ -lactams. Isolates were additionally non-susceptible to ciprofloxacin, erythromycin, gentamicin and tetracycline (34.1%, 14/41); ciprofloxacin, gentamicin and tetracycline (14.6% 6/41); ciprofloxacin, erythromycin and gentamicin (14.6%, 6/41); ciprofloxacin, erythromycin and tetracycline (7.3%, 3/41); ciprofloxacin and tetracycline (4.9%, 2/41) and erythromycin (4.9%, 2/41). Single isolates were non-susceptible to ciprofloxacin, erythromycin, fusidic acid and tetracycline; ciprofloxacin, erythromycin, tetracycline and co-trimoxazole; ciprofloxacin, fusidic acid and co-trimoxazole; erythromycin, gentamicin and tetracycline; ciprofloxacin and gentamicin; and ciprofloxacin and erythromycin. Overall 70.7% of ST45-V<sub>T</sub> were community-onset.

ST1-IV accounted for 10.0% of CA-MRSA and was isolated in all regions of Australia except the Australian Capital Territory, ranging from 6.1% in New South Wales to 100% in Tasmania (Table 5). Typically PVL negative, 65.7% of isolates were resistant to the  $\beta$ -lactams only (23/35). Other isolates were additionally resistant to erythromycin (17.1%, 6/35); and erythromycin and fusidic acid (5.7%, 2/35). Single isolates were resistant to either ciprofloxacin; ciprofloxacin and co-trimoxazole; or gentamicin. Overall 82.9% of ST1-IV were community-onset.

ST30-IV accounted for 6.0% of CA-MRSA and was isolated in all regions of Australia except the Australian Capital Territory, the Northern Territory and Tasmania, ranging from 2.5% in Victoria to 13.8% in Queensland (Table 5). ST30-IV isolates, of which 81.0% were PVL positive, were typically resistant to the  $\beta$ -lactams

**Table 5: The number and proportion of the major community-associated methicillin-resistant *Staphylococcus aureus* (MRSA) multilocus sequence types, Australia (> 10 isolates), 2018, by region**

Type	ACT		NSW		NT		Qld		SA		Tas		Vic		WA		Aus	
	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%	n	%
ST93-IV	1	14.3%	15	18.3%	19	67.9%	17	26.2%	13	46.4%	-	-	6	15.0%	28	29.8%	99	28.5%
ST5-IV	-	-	7	7.3%	3	10.7%	14	21.5%	2	7.1%	-	-	4	7.5%	14	13.8%	44	11.8%
ST45-V	2	28.6%	26	31.7%	1	3.6%	1	1.5%	3	10.7%	-	-	7	17.5%	1	1.1%	41	11.8%
ST1-IV	-	-	5	6.1%	2	7.1%	5	7.7%	4	14.3%	3	100.0%	5	12.5%	11	11.7%	35	10.1%
ST30-IV	-	-	5	6.1%	-	-	9	13.8%	1	3.6%	-	-	1	2.5%	5	5.3%	21	6.1%
ST97-IV	1	14.3%	3	3.7%	-	-	7	10.8%	-	-	-	-	1	2.5%	2	2.1%	14	4.0%
ST78-IV	-	-	3	3.7%	-	-	-	-	-	-	-	-	-	-	10	10.6%	13	3.7%
Other	3	42.9%	19	23.2%	3	10.7%	12	18.5%	5	17.9%	-	-	17	42.5%	24	25.5%	83	23.9%
<b>Total</b>	<b>7</b>	<b>100.0%</b>	<b>83</b>	<b>100.0%</b>	<b>28</b>	<b>100.0%</b>	<b>65</b>	<b>100.0%</b>	<b>28</b>	<b>100.0%</b>	<b>3</b>	<b>100.0%</b>	<b>41</b>	<b>100.0%</b>	<b>95</b>	<b>100.0%</b>	<b>350</b>	<b>100.0%</b>

ACT = Australian Capital Territory; NSW = New South Wales; NT = Northern Territory; Qld = Queensland; SA = South Australia; Tas = Tasmania; Vic = Victoria; WA = Western Australia; Aus = Australia

only (85.7%, 18/21). Single isolates were resistant to either erythromycin; ciprofloxacin; or gentamicin, rifampicin and tetracycline. Overall 90.5% of ST30-IV were community-onset.

ST97-IV accounted for 4.0% of CA-MRSA and was isolated in all regions of Australia except the Northern Territory, South Australia and Tasmania, ranging from 2.1% in Western Australia to 14.3% in the Australian Capital Territory (Table 5). Typically PVL negative, 64.3% of isolates were resistant to the  $\beta$ -lactams only (9/14). Other isolates were additionally resistant to erythromycin (25.8%, 3/14). Single isolates were resistant to erythromycin, fusidic acid and co-trimoxazole or co-trimoxazole alone. Overall 85.7% of ST97-IV were community-onset.

ST78-IV accounted for 3.7% of CA-MRSA and was predominantly isolated in Western Australia (Table 5). Isolates were resistant to the  $\beta$ -lactams and erythromycin (87.5%, 9/13); two isolates resistant to the  $\beta$ -lactams only; one isolate additionally resistant to ciprofloxacin and one to tetracycline. Overall 76.9% of ST78-IV were community-onset.

Overall 84.7% of CA-MRSA were non-multiresistant including 50.4% resistant to the  $\beta$ -lactams only. A substantial increase was seen in multi-resistant CA-MRSA isolates in ASSOP 2018 (15.3%), from 9.2% in ASSOP 2013.<sup>11</sup> Multi-resistance was primarily due to the ST45-V<sub>T</sub> clone.

### Panton-Valentine leucocidin

Overall 145 (31.6%) of MRSA were PVL positive, all of which were CA-MRSA (Table 3).

## Discussion

The AGAR surveillance programmes collect data on antimicrobial resistance, focussing on bloodstream infections caused by *S. aureus*, *Enterococcus* and *Enterobacteriaceae*. All data collected in the AGAR programs are generated as part of routine patient care in Australia, with most available through laboratory and hospital

bed management information systems. Isolates are referred to a central laboratory where strain and antimicrobial resistance determinant characterisation is performed. As the programmes are similar to those conducted in Europe,<sup>19</sup> comparison of Australia's antimicrobial resistance data with other countries is possible.

In ASSOP 2018, 17.4% (95% CI 16.0–18.9) of the 2,673 SAB episodes were methicillin resistant. In the 2018 European Centre for Disease Prevention and Control and Prevention (ECDC) SAB surveillance program, the European Union / European Economic Area (EU/EEA) population-weighted mean percentage of *S. aureus* resistant to methicillin was 16.4% (95% CI 16–17), ranging from 0% (95% CI 0–4) in Iceland to 43% (95% CI 39–49) in Romania.<sup>20</sup>

Europe has seen the EU/EEA population-weighted mean percentage decrease markedly from 23.2% in 2009 to 16.4% in 2018. The percentage of methicillin-resistant SAB in Australia however has remained stable over the previous five years of ASSOP ranging from 19.1% in 2013 to 19.0% in 2017 with a non-significant reduction 17.4% in 2018.

A decrease in methicillin-resistant SAB has been reported in several parts of the world<sup>20,21</sup> and is believed to be due to the implementation of antimicrobial stewardship and a package of improved infection control procedures including hand hygiene, MRSA screening and decolonisation, patient isolation and infection prevention care bundles.<sup>22–26</sup> In Australia, although we have not seen a significant decrease in MRSA bacteraemia, we have observed significant decreases in HA-MRSA from 41.0% to 23.2% ( $p < 0.0001$ ) and hospital-onset MRSA from 38.0% to 22.2% ( $p < 0.0001$ ) over the six ASSOP surveys.<sup>11,27,28,29,30</sup>

Because of the increased burden of CA-MRSA bacteraemia in Australia, a significant reduction in the overall proportion of SAB due to MRSA may prove problematic.

In ASSOP 2018, the all-cause mortality at 30 days was 14.2% (95% CI 12.7–15.8). The MRSA-

associated SAB mortality was 17.1% (95% CI 15.5–18.8), which was not significantly higher ( $p = 0.1$ ) than the MSSA-associated SAB mortality (13.6%, 95% CI 12.2–15.1).

With the exception of the  $\beta$ -lactams and erythromycin, antimicrobial resistance in MSSA remains rare. However for MRSA, in addition to the  $\beta$ -lactams, approximately 25% of isolates were resistant to erythromycin and ciprofloxacin and approximately 5% to co-trimoxazole, tetracycline and gentamicin. Resistance was largely attributable to two healthcare-associated MRSA clones, ST22-IV [2B] (EMRSA-15), which is typically ciprofloxacin and erythromycin resistant, and ST239-III [3A] (Aus-2/3 EMRSA) which is typically erythromycin, clindamycin, ciprofloxacin, co-trimoxazole, tetracycline and gentamicin resistant. In the early 1980s, multi-resistant ST239-III [3A] (Aus-2/3 EMRSA) was the dominant HA-MRSA clone in Australian hospitals. However, in 2013 the first ASSOP survey showed that ST22-IV [2B] (EMRSA-15) was replacing ST239-III [3A] (Aus-2/3 EMRSA) as the most prevalent HA-MRSA and this change has occurred throughout most of the country.<sup>31</sup> In ASSOP 2018 approximately 18% of MRSA were characterised as ST22-IV [2B] (EMRSA-15). Community-associated MRSA, in particular the ST45-V<sub>T</sub> clone (9.1% of MRSA), has acquired multiple antimicrobial resistance determinants including ciprofloxacin, erythromycin, clindamycin, gentamicin and tetracycline.

Resistance was not detected for vancomycin, linezolid or teicoplanin when CLSI interpretive criteria were applied. However two isolates were teicoplanin non-susceptible when EUCAST criteria were applied. There were six isolates resistant to daptomycin by both CLSI and EUCAST criteria.

Approximately 14.8% of SAB caused by CA-MRSA were hospital-onset. Transmission of CA-MRSA in Australian hospitals is thought to be rare.<sup>32,33</sup> It is likely that many of the hospital-onset CA-MRSA SAB infections reported in ASSOP 2018 were caused by the patient's own colonising strains acquired prior to admission.

In Australia, CA-MRSA clones such as PVL-positive ST93-IV [2B] (Queensland CA-MRSA) are well-established in the community and therefore it is important to monitor antimicrobial resistance patterns in both community- and healthcare-associated SAB as this information will guide therapeutic practices in treating *S. aureus* sepsis.

In conclusion, ASSOP 2018 has demonstrated that antimicrobial resistance in SAB in Australia continues to be a major problem and continues to be associated with a high mortality. This may be due, in part, to the high prevalence of methicillin-resistant SAB in Australia, which is notably higher than in most EU/EEA countries. Consequently MRSA must remain a public health priority and continuous surveillance of SAB and its outcomes and the implementation of comprehensive MRSA strategies targeting hospitals and long-term care facilities are essential.

## Acknowledgments

This study was funded by a grant from the Australian Commission on Safety and Quality in Healthcare.

Members of the AGAR in 2018 were:

### Australian Capital Territory

Peter Collignon and Susan Bradbury,  
Canberra Hospital

### New South Wales

Thomas Gottlieb and Steven Siarakas, Concord  
Hospital

James Branley and Donna Barbaro,  
Nepean Hospital

Peter Huntington, Royal North Shore Hospital

Sebastiaan van Hal and Alicia Beukers, Royal  
Prince Alfred Hospital

Jon Iredell and Andrew Ginn,  
Westmead Hospital

Rod Givney and Kimberly Ross,  
John Hunter Hospital

Peter Newton and Melissa Hoddle,  
Wollongong Hospital

Jock Harkness and David Lorenz,  
St Vincent's Hospital

### **Northern Territory**

Rob Baird and Jann Hennessy,  
Royal Darwin Hospital

James McLeod, Alice Springs Hospital

### **Queensland**

Enzo Binotto and Bronwyn Thomsett,  
Pathology Queensland Cairns Base Hospital

Graeme Nimmo and Narelle George, Pathology  
Queensland Central Laboratory, Royal Brisbane  
and Women's Hospital

Petra Derrington and Cheryl Curtis, Pathology  
Queensland Gold Coast Hospital

Robert Horvath and Laura Martin, Pathology  
Queensland Prince Charles Hospital

Naomi Runnegar and Joel Douglas, Pathology  
Queensland Princess Alexandra Hospital

Jennifer Robson and Georgia Peachey, Sullivan  
Nicolaides Pathology, Greenslopes Hospital

Clare Nourse, Lady Cilento Children's Hospital

### **South Australia**

Kelly Papanoum and Xiao Ming Chen, SA  
Pathology (Flinders Medical Centre)

Morgyn Warner and Kija Smith, SA Pathology  
(Royal Adelaide Hospital and Women's and  
Children's Hospital)

### **Tasmania**

Louise Cooley and David Jones,  
Royal Hobart Hospital

Pankaja Kalukottege and Kathy Wilcox,  
Launceston General Hospital

### **Victoria**

Denis Spelman and Chris Lee, Alfred Hospital

Marcel Leroi and Elizabeth Grabsch,  
Austin Health

Tony Korman and Despina Kotsanas,  
Monash Medical Centre and Monash  
Children's Hospital

Andrew Daley and Gena Gonis, Royal Women's  
and Children's Hospital

Mary Jo Waters and Lisa Brenton,  
St Vincent's Hospital

### **Western Australia**

David McGeachie and Denise Daley, PathWest  
Laboratory Medicine – WA Fiona Stanley  
Hospital

Ronan Murray and Jacinta Bowman, PathWest  
Laboratory Medicine – WA Sir Charles  
Gairdner Hospital

Michael Leung, PathWest Laboratory Medicine  
– Northwest WA

Owen Robinson and Geoffrey Coombs,  
PathWest Laboratory Medicine – WA Royal  
Perth Hospital

Sudha Pottumarthy-Boddu and Fay Kappler,  
Australian Clinical Laboratories, St John of  
God Hospital, Murdoch

Shalinie Perera and Ian Meyer, Western Diagnostic Pathology, Joondalup Hospital

Christopher Blyth, PathWest Laboratory Medicine – WA Princess Margaret Hospital for Children

## Author Details

Prof Geoffrey W Coombs,<sup>1,2</sup>

Ms Denise A Daley,<sup>2,3</sup>

Dr Shakeel Mowlaboccus,<sup>1</sup>

Ms Yung Thin Lee,<sup>1</sup>

Dr Stanley Pang,<sup>1,2</sup>

on behalf of the Australian Group on Antimicrobial Resistance.

1. Antimicrobial Resistance and Infectious Disease (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia
2. Department of Microbiology, PathWest Laboratory Medicine-WA, Fiona Stanley Hospital, Murdoch, Western Australia, Australia
3. Australian Group on Antimicrobial Resistance, Fiona Stanley Hospital, Murdoch, Western Australia, Australia

## Corresponding Author

Prof Geoffrey Coombs

Antimicrobial Resistance and Infectious Disease (AMRID) Research Laboratory, Murdoch University, Murdoch, Western Australia, Australia

Telephone: +61 8 6152 2397

Email: g.coombs@murdoch.edu.au

## References

1. Laupland KB. Incidence of bloodstream infection: a review of population-based studies. *Clin Microbiol Infect.* 2013;19(6):492–500.
2. Johnson AP, Pearson A, Duckworth G. Surveillance and epidemiology of MRSA bacteraemia in the UK. *J Antimicrob Chemother.* 2005;56(3):455–62.
3. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Török ME et al. Clinical management of *Staphylococcus aureus* bacteraemia. *Lancet Infect Dis.* 2011;11(3):208–22.
4. Collignon P, Nimmo GR, Gottlieb T, Gosbell IB for the Australian Group on Antimicrobial Resistance. *Staphylococcus aureus* bacteremia, Australia. *Emerg Infect Dis.* 2005;11(4):554–61.
5. Frederiksen MS, Espersen F, Frimodt-Møller N, Jensen AG, Larsen AR, Pallesen LV et al. Changing epidemiology of pediatric *Staphylococcus aureus* bacteremia in Denmark from 1971 through 2000. *Pediatr Infect Dis J.* 2007;26(5):398–405.
6. Benfield T, Espersen F, Frimodt-Møller N, Jensen AG, Larsen AR, Pallesen LV et al. Increasing incidence but decreasing in-hospital mortality of adult *Staphylococcus aureus* bacteraemia between 1981 and 2000. *Clin Microbiol Infect.* 2007;13(3):257–63.
7. van Hal SJ, Jensen SO, Vaska VL, Espedido BA, Paterson DL, Gosbell IB. Predictors of mortality in *Staphylococcus aureus* bactere-

- mia. *Clin Microbiol Rev.* 2012;25(2):362–86.
8. Kaasch AJ, Barlow G, Edgeworth JD, Fowler VG Jr, Hellmich M, Hopkins S et al. *Staphylococcus aureus* bloodstream infection: a pooled analysis of five prospective, observational studies. *J Infect.* 2014;68(3):242–51.
  9. Turnidge JD, Kotsanas D, Munckhof W, Roberts S, Bennett CM, Nimmo GR et al. *Staphylococcus aureus* bacteraemia: a major cause of mortality in Australia and New Zealand. *Med J Aust.* 2009;191(7):368–73.
  10. Nimmo GR, Bell JM, Collignon PJ for the Australian Group on Antimicrobial Resistance. Fifteen years of surveillance by the Australian Group for Antimicrobial Resistance (AGAR). *Commun Dis Intell Q Rep.* 2003;27(Suppl):S47–54.
  11. Coombs GW, Nimmo GR, Daly DA, Le TT, Pearson JC, Tan HL et al. Australian *Staphylococcus aureus* Sepsis Outcome Programme annual report, 2013. *Commun Dis Intell Q Rep.* 2014;38(4):E309–19.
  12. Clinical and Laboratory Standards Institute (CLSI). *M100-S24 Performance standards for antimicrobial susceptibility testing; Twenty-fourth informational supplement.* Villanova, PA, USA, 2014.
  13. European Committee on Antimicrobial Susceptibility Testing (EUCAST). *Clinical breakpoints – bacteria v 4.0.* 2014. Available from: [http://www.eucast.org/ast\\_of\\_bacteria/previous\\_versions\\_of\\_documents/](http://www.eucast.org/ast_of_bacteria/previous_versions_of_documents/)
  14. Seemann T, Goncalves da Silva A, Bulach DM, Schultz MB, Kwong JC, Howden BP. Nullarbor. San Francisco; Github. [Accessed: 03 Jun 2016.] Available from: <https://github.com/tseemann/nullarbor>
  15. Bartels MD, Petersen A, Worning P, Nielsen JB, Larner-Svensson H, Johansen HK et al. Comparing whole-genome sequencing with Sanger sequencing for spa typing of methicillin-resistant *Staphylococcus aureus*. *J Clin. Microbiol.* 2014;52(12):4305–8.
  16. Clausen PTLC, Aarestrup FM, Lund O. Rapid and precise alignment of raw reads against redundant databases with KMA. *BMC Bioinformatics.* 2018;19(1): 307.
  17. International Working Group on The Classification of Staphylococcal Cassette Chromosome Elements (IWG-SCC). Classification of staphylococcal cassette chromosome mec (SCCmec): guidelines for reporting novel SCCmec elements. *Antimicrob Agents Chemother.* 2009;56(12):4961–7.
  18. Kondo Y, Ito T, Ma XX, Watanabe S, Kreiswirth BN, Etienne J et al. Combination of multiplex PCRs for staphylococcal cassette chromosome mec type assignment: rapid identification system for mec, ccr and major difference in junkyard regions. *Antimicrob Agents Chemother.* 2007;51(1):264–74.
  19. European Centre for Disease Prevention and Control (ECDC). Surveillance of antimicrobial resistance in Europe 2018. [Internet.] European Centre for Disease Prevention and Control; 2019. Available from: <https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2018>
  20. Johnson AP, Davies J, Guy R, Abernethy J, Sheridan E, Pearson A et al. Mandatory surveillance of methicillin-resistant *Staphylococcus aureus* (MRSA) bacteraemia in England: the first 10 years. *J Antimicrob Chemother.* 2012;67(4):802–9.
  21. de Kraker MEA, Davey PG, Grundmann H, BURDEN study group. Mortality and hospital stay associated with resistant *Staphylococcus aureus* and *Escherichia coli* bacteremia: estimating the burden of antibiotic resistance in Europe. *PLoS Med.* 2011;8(10):e1001104.
  22. Johnson PDR, Martin R, Burrell LJ, Grabisch EA, Kirsas SW, O’Keeffe J et al. Efficacy of an alcohol/chlorhexidine hand hygiene

- program in a hospital with high rates of nosocomial methicillin-resistant *Staphylococcus aureus* (MRSA) infection. *Med J Aust*. 2005;183(10):509–14.
23. Vos MC, Behrendt MD, Melles DC, Mollema FP, de Groot W, Parlevliet G et al. 5 years of experience implementing a methicillin-resistant *Staphylococcus aureus* search and destroy policy at the largest university medical center in the Netherlands. *Infect Control Hosp Epidemiol*. 2009;30(10):977–84.
  24. Grayson ML, Jarvie LJ, Martin R, Johnson PD, Jodoin ME, McMullan C et al. Significant reductions in methicillin-resistant *Staphylococcus aureus* bacteraemia and clinical isolates associated with a multisite, hand hygiene culture-change program and subsequent successful statewide roll-out. *Med J Aust*. 2008;188(11):633–40.
  25. Kim YC, Kim MH, Song JE, Ahn JY, Oh DH, Kweon OM et al. Trend of methicillin-resistant *Staphylococcus aureus* (MRSA) bacteremia in an institution with a high rate of MRSA after the reinforcement of antibiotic stewardship and hand hygiene. *Am J Infect Control*. 2013;41(5):e39–43.
  26. Lawes T, Edwards B, López-Lozano JM, Gould I. Trends in *Staphylococcus aureus* bacteraemia and impacts of infection control practices including universal MRSA admission screening in a hospital in Scotland, 2006–2010: retrospective cohort study and time-series intervention analysis. *BMJ Open*. 2012;2(3). <https://doi.org/10.1136/bmjopen-2011-000797>.
  27. Coombs GW, Daley DA, Lee YT, Pearson JC, Robinson JO, Nimmo GR et al. Australian Group on Antimicrobial Resistance Australian *Staphylococcus aureus* Sepsis Outcome Programme annual report, 2014. *Commun Dis Intell Q Rep*. 2016;40(2):E244–54.
  28. Coombs GW, Daley DA, Lee YT, Pang S for the Australian Group on Antimicrobial Resistance. Australian Group on Antimicrobial Resistance (AGAR) Australian *Staphylococcus aureus* Sepsis Outcome Programme (ASSOP) Annual Report 2016. *Commun Dis Intell* (2018). 2018;42. pii: S2209-6051(18)00021-0.
  29. Coombs GW, Daley DA, Lee YT, Pang S, Bell JM, Turnidge JD et al. Australian Group on Antimicrobial Resistance (AGAR) Australian *Staphylococcus aureus* Sepsis Outcome Programme (ASSOP) Annual Report 2015. *Commun Dis Intell*(2018). 2018;42. pii: S2209-6051(18)00016-7.
  30. Coombs GW, Daley DA, Lee YT, Pang S. Australian Group on Antimicrobial Resistance (AGAR) Australian *Staphylococcus aureus* Sepsis Outcome Programme (ASSOP) Annual Report 2017. *Commun Dis Intell* (2018). 2019;43. <https://doi.org/10.33321/cdi.2019.43.43>.
  31. Coombs GW, Pearson JC, Nimmo GR, Collignon PJ, Bell JM, McLaws ML et al. Antimicrobial susceptibility of *Staphylococcus aureus* and molecular epidemiology of methicillin-resistant *S. aureus* isolated from Australian hospital inpatients: Report from the Australian Group on Antimicrobial Resistance 2011 *Staphylococcus aureus* Surveillance Programme. *J Glob Antimicrob Resist*. 2013;1(3):149–56.
  32. O'Brien FG, Pearman JW, Gracey M, Riley TV, Grubb WB. Community strain of methicillin-resistant *Staphylococcus aureus* involved in a hospital outbreak. *J Clin Microbiol*. 1999;37(9):2858–62.
  33. Schlebusch S, Price GR, Hinds S, Nourse C, Schooneveldt JM, Tilse MH et al. First outbreak of PVL-positive nonmultiresistant MRSA in a neonatal ICU in Australia: comparison of MALDI-TOF and SNP-plus-binary gene typing. *Eur J Clin Microbiol Infect Dis*. 2010;29(10):1311–4.